Lv11
60 积分 2023-11-15 加入
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
1小时前
已完结
Discovery of TYRA-300: First Oral Selective FGFR3 Inhibitor for the Treatment of Urothelial Cancers and Achondroplasia
16天前
已完结
Fibroblast growth factor receptor inhibitor erdafitinib promotes Mcl-1 degradation and synergistically induces apoptosis with Bcl-xL/Bcl-2 inhibitor in urothelial cancer cells
2个月前
已完结
Discovery of novel EGFR-PROTACs capable of degradation of multiple EGFR-mutated proteins
3个月前
已完结
Transgenic and knock-out mice for deciphering the roles of EGFR ligands
3个月前
已完结
Erdafitinib for the treatment of metastatic bladder cancer
4个月前
已完结
Structural investigation of erdafitinib, an anticancer drug, with ctDNA: A spectroscopic and computational study
4个月前
已关闭
TAS‐120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure
4个月前
已完结
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
4个月前
已完结
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
4个月前
已完结
皖公网安备34019202002308
